NMPA Conditionally Approves Atrasentan Hydrochloride Tablets for IgA Nephropathy

Source: Website of the National Medical Products Administration

Recently, the National Medical Products Administration (NMPA) has granted conditional approval for the marketing of Novartis Pharma Schweiz AG's Class 1 innovative drug, Atrasentan Hydrochloride Tablets, through a priority review process. The drug is indicated for reducing proteinuria in adult patients with primary Immunoglobulin A Nephropathy (IgA Nephropathy) who are at risk of rapid disease progression, generally defined as having a Urine Protein-to-Creatinine Ratio (UPCR) ≥ 1.5 g/g. The approval of this drug provides patients with a new therapeutic option.